XERS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Xeris Biopharma Holdings Inc (XERS) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company shows strong revenue growth, the negative net income, declining EPS, and bearish technical indicators suggest caution. Additionally, there are no significant positive catalysts or trading signals to support immediate action.
The stock is in a bearish trend with SMA_200 > SMA_20 > SMA_5. The MACD histogram is below 0 and negatively contracting, indicating weak momentum. RSI is neutral at 42.134, and the price is trading near the pivot level of 5.64. Key resistance is at 5.87, and support is at 5.411.
Revenue increased by 37.06% YoY in Q3 2025, and gross margin improved by 16.60% YoY to 81.57%.
Net income dropped by -103.95% YoY, and EPS fell to 0, down -100% YoY. There are no recent news events or significant insider or hedge fund trading trends to act as catalysts. Technical indicators are bearish.
In Q3 2025, revenue grew significantly to $74.38M (+37.06% YoY), but net income dropped to $621K (-103.95% YoY), and EPS fell to 0 (-100% YoY). Gross margin improved to 81.57% (+16.60% YoY).
No recent analyst rating or price target changes are available.
